Quest Diagnostics Incorporated (DGX)

Currency in USD
231.91
-1.10(-0.47%)
Closed·
231.950.00(0.00%)
·
DGX is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
230.54233.44
52 wk Range
170.53240.13
Key Statistics
Prev. Close
233.01
Open
232.84
Day's Range
230.54-233.44
52 wk Range
170.53-240.13
Volume
583.29K
Average Vol. (3m)
927.02K
1-Year Change
34.4874%
Book Value / Share
67.9
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
DGX Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
245.87
Upside
+6.02%
Members' Sentiments
Bearish
Bullish
ProTips
Has raised its dividend for 14 consecutive years
Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell

Analyst Ratings

9 Buy
7 Hold
1 Sell
Ratings:
17 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 245.87
(+6.02% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
JPMorgan
Hold250.00+7.80%220.00MaintainJul 28, 2026
Morgan Stanley
Buy260.00+12.11%226.00MaintainJul 24, 2026
UBS
Hold232.00+0.04%220.00MaintainJul 24, 2026
UBS
Hold232.00+0.04%220.00MaintainJul 24, 2026
Evercore ISI
Hold240.00+3.49%225.00MaintainJul 24, 2026

Quest Diagnostics Incorporated Earnings Call Summary for Q2/2026

  • Quest Diagnostics Q2 adjusted EPS of $3.12 beat estimates by 10.64%; revenue rose 10.2% to $3.04B, topping forecasts by $70M amid strong demand.
  • Company raised FY2026 guidance to $11.95B-$12.05B revenue and $11.05-$11.25 adjusted EPS; stock surged 11.15% to $233.22 in premarket trading.
  • Total requisition volume jumped 13.1% YoY driven by double-digit hospital growth, including Corewell Health partnership and consumer testing expansion.
  • Adjusted operating margin declined 40bps YoY to 16.5% despite revenue growth; higher Project Nova and fuel costs expected to pressure H2 profitability.
  • Management highlighted advanced diagnostics growth in brain health, oncology, and cardiometabolic testing; tests per requisition rose above 4.5 from pre-COVID 3.5-4.
Last Updated: 07/23/2026, 09:39 AM
Read Full Transcript
Quest Diagnostics investor slides for Q2/2026
Quest Diagnostics Q2 2026 slides
Last Update: Jul 23, 2026
See full investor slides

Earnings

Latest Release
Jul 23, 2026
EPS / Forecast
3.12 / 2.82
Revenue / Forecast
3.04B / 2.97B
EPS Revisions
Last 90 days

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 9.42%
Dividend Yield
1.47%
Industry Median 2.03%
Annualized Payout
3.44
Paid quarterly
5-Years Growth
+7.06%
Growth Streak

DGX Income Statement

Compare DGX to Peers and Sector

Metrics to compare
DGX
Peers
Sector
Relationship
P/E Ratio
24.2x19.7x−0.4x
PEG Ratio
1.890.760.00
Price / Book
3.4x2.4x2.6x
Price / LTM Sales
2.2x1.8x3.0x
Upside (Analyst Target)
7.4%24.9%56.0%
Fair Value Upside
Unlock16.9%9.1%Unlock

Quest Diagnostics Incorporated provides diagnostic testing and services in the United States. The company develops and delivers diagnostic information services, such as routine, non-routine and advanced clinical testing, anatomic pathology testing, and other diagnostic information services. It also provides services under the Quest Diagnostics brand, as well as under the AmeriPath, Dermpath Diagnostics, ExamOne, and Quanum brands to physicians, hospitals, patients and consumers, health plans, government agencies, employers, retailers, pharmaceutical companies and insurers commercial clinical laboratories, and accountable care organizations through a network of laboratories, patient service centers, phlebotomists in physician offices, call centers and mobile phlebotomists, nurses, and other health and wellness professionals. In addition, the company offers risk assessment services for the life insurance industry; healthcare IT healthcare providers and payers; testing and medical director services at hospital laboratories; test offerings in cardiometabolic and endocrine; cancer; clinical drug monitoring and toxicology; infectious disease, including autoimmune; neurology diagnostics, including Alzheimer’s disease; and women’s health, such as prenatal genetic; workplace drug testing, testing urine, hair, and oral fluid specimens services; and employer population health services, including biometric screenings, flu shots, and related preventative services. Further, it provides population health solutions; extended care services; develops in vitro diagnostic tests; laboratory diagnostic information and digital health connectivity systems; underwriting support services, including data gathering, paramedical examinations, and clinical laboratory testing and analytics; and national specimen collection and health data solutions. Quest Diagnostics Incorporated was founded in 1967 and is headquartered in Secaucus, New Jersey.

Ownership

Ownership Overview

Type
Common Stock Held% of Shares OutstandingMarket Value
Mutual Funds & ETFs
57.90M52.46%13.49B
Other Institutional Investors
49.15M44.53%11.45B
Public Companies & Retail Investors
3.32M3.01%774.53M
Total
110.37M100.00%25.72B

Top Holders

Holder
% of holding
Shares Held
Date Reported
Value (In 1,000s)
BlackRock, Inc.8.31%9,172,2922,137,236
Vanguard Capital Management, LLC6.47%7,145,6721,665,013

People Also Watch

307.42
LH
-0.58%
680.20
PWR
+1.92%
829.50
MU
+0.79%
374.74
WAT
-0.68%
146.64
GLW
+6.07%

FAQ

What Is the Quest Diagnostics (DGX) Stock Price Today?

The Quest Diagnostics stock price today is 231.91 USD.

What Stock Exchange Does Quest Diagnostics Trade On?

Quest Diagnostics is listed and trades on the New York Stock Exchange.

What Is the Stock Symbol for Quest Diagnostics?

The stock symbol for Quest Diagnostics is "DGX."

Does Quest Diagnostics Pay Dividends? What’s The Current Dividend Yield?

The Quest Diagnostics dividend yield is 1.48%.

What Is the Quest Diagnostics Market Cap?

As of today, Quest Diagnostics market cap is 25.72B USD.

What Is Quest Diagnostics's Earnings Per Share (TTM)?

The Quest Diagnostics EPS (TTM) is 9.42.

When Is the Next Quest Diagnostics Earnings Date?

Quest Diagnostics will release its next earnings report on Oct 27, 2026.

From a Technical Analysis Perspective, Is DGX a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Quest Diagnostics Stock Split?

Quest Diagnostics has split 2 times.

How Many Employees Does Quest Diagnostics Have?

Quest Diagnostics has 51500 employees.

What is the current trading status of Quest Diagnostics (DGX)?

As of Aug 04, 2026, Quest Diagnostics (DGX) is trading at a price of 231.91 USD, with a previous close of 233.01 USD. The stock has fluctuated within a day range of 230.54 USD to 233.44 USD, while its 52-week range spans from 170.53 USD to 240.13 USD.

What Is Quest Diagnostics (DGX) Price Target According to Analysts?

The average 12-month price target for Quest Diagnostics is 245.87 USD, with a high estimate of 265 USD and a low estimate of 204 USD. 9 analysts recommend buying the stock, while 1 suggest selling, leading to an overall rating of Buy. The stock has an +6.02% Upside potential.

What Is the DGX Premarket Price?

DGX's last pre-market stock price is 234.06 USD. The pre-market share volume is 120.00, and the stock has decreased by 1.05, or 0.45%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.